BBN as an urothelial carcinogen

In Vivo

Volumn 26, Issue 4, 2012, Pages 727-739

  Vasconcelos Nobrega C ^a   Colaco A ^b   Lopes, C ^c   Oliveira, P A ^b  

^a POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

Author keywords

Carcinogenesis; N butyl N (4 hydroxybutyl)nitrosamine; Review; Tumours; Urothelial

Indexed keywords

N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; CARCINOGEN;

ANIMAL MODEL; BIOLUMINESCENCE; BLADDER CANCER; BLADDER CARCINOGENESIS; BLADDER TUMOR; C57BL MOUSE; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DNA DAMAGE; ECHOGRAPHY; ENDOSCOPY; EXPERIMENTAL MODEL; FOREIGN BODY; GENOTOXICITY; HUMAN; IN VIVO STUDY; MUTATION; NODULAR HYPERPLASIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVIEW; TRANSGENIC ANIMAL; TUMOR CELL LINE; URINARY TRACT TUMOR; UROLITHIASIS; WILD TYPE; CHEMICALLY INDUCED DISORDER;

BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 84865076269     PISSN: 0258851X     EISSN: 17917549     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Kompier LC, Lurkin I, van der Aa MNM, van Rhijn BWG, van der Kwast TH and Zwarthoff EC: FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. Plos One 5(11): 1-13, 2010.
3. Cohen SM: Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 30(6): 663-671, 2002.
4. Grignon DJ: The current classification of urothelial neoplasms. Mod Pathol 22: S60-S69, 2009.
5. Petraki CD and Spikas CP: Non-papillary urothelial lesions of the urinary bladder: morphological classification and immunohistochemical markers. In Vivo 22: 493-502, 2008.
6. Oliveira PA, Colaço A, De la Cruz Palomino LF and Lopes C: Experimental bladder carcinogenesis - rodent models. Exp Oncol 28: 2-11, 2006.
7. Arentsen HC, Hendricksen K, Oosterwijk E and Witjes JA: Experimental rat bladder urothelial cell carcinoma models. World J Urol 27: 313-317, 2009.
8. Clayson DB, Fishbein L and Cohen SM: Effects of stones and other physical factors on the induction of rodent bladder cancer. Food Chem Toxicol 33(9): 771-784, 1995.
9. van Moorselaar RJA, Ichikawa T, Schaafsma HE, Jap PHK, Isaacs JT, van Stratum P, Ramaekers FCS, Debruyne FMJ and Schalken JA: The rat bladder tumor model system RBT resembles phenotypically and cytogenetically human superficial transitional cell carcinoma. Urol Res 21: 413-421, 1993.
10. Martin-Sanz P, Mayoral R, Casado M and Bosca L: COX-2 in liver, from regeneration to hepatocarcinogenesis: What we have learned from animal models? World J Gastroenterol 16(12): 1430-1435, 2010.
11. Steele VE and Lubet RA: The use of animal models for cancer chemoprevention drug development. Semin Oncol 37(4): 327-338, 2010.
12. Zhang ZT, Pak J, Shapiro E, Sun TT and Wu XR: Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 59: 3512-3517, 1999.
13. Johnson AM, O'Connell MJ, Messing EM and Reeder JE: Decreased bladder cancer growth in parous mice. Urology 72(3): 470-473, 2008.
14. He F, Mo L, Zheng XY, Hu C, Lepor H, Lee E Y-HP, Sun T-T and Wu XR: Deficiency of pRb family proteins and p53 in invasive urothelial tumorigenesis. Cancer Res 69(24): 9413-9421, 2009.
15. Stone R, Sabichi AL, Gill J, Lee I-I, Adegboyega P, Dai MS, Loganantharaj R, Trutschl M, Cvek U and Clifford JL: Identification of genes correlated with early stage bladder cancer progression. Cancer Prev Res (Phila) 3(6): 776-786, 2010.
16. Grippo PJ and Sandgren EP: Highly invasive transitional cell carcinoma of the bladder in a Simian virus 40 T-antigen transgenic mouse model. Am J Pathol 157(3): 805-813, 2000.
17. Iida K, Itoh K, Kumagai Y, Oyasu R, Hattori K, Kawai K, Shimazui T, Akaza H and Yamamoto M: Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 64: 6424-6431, 2004.
18. Ding Y, Paonessay JD, Randall KL, Argoti D, Chen L, Vouros P and Zhang Y: Sulforaphane inhibits 4-aminobiphenyl-induced DNA damage in bladder cells and tissues. Carcinogenesis 31(11): 1999-2003, 2010.
19. Slocum SL and Kensler TW: Nrf2: control of sensitivity to carcinogens. Arch Toxicol 85(4): 273-284, 2011.
20. Zhang Z-T, Pak J, Huang H-Y, Shapiro E, Sun T-T, Pellicer A and Wu XR: Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 20: 1973-1980, 2001.
21. Cheng J, Huang H, Pak J, Shapiro E, Sun T-T, Cordon-Cardo C, Waldman FM and Wu XR: Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder. Cancer Res 63: 179-185, 2003.
22. Ahmad, R Patel1, Y Liu, LB Singh, Taketo MM, Wu X-R, Leung HY and Sansom OJ: Ras mutation cooperates with b-catenin activation to drive bladder tumourigenesis. Cell Death Dis 2: e124, 2011.
23. Ozaki K, Sukata T, Yamamoto S, Uwagawa S, Seki T, Kawasaki H, Yoshitake A, Wanibuchi H, Koide A, Mori Y and Fukushima S: High susceptibility of p53 (+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res 58: 3806-3811, 1998.
24. Sills RC, French JE and Cunningham ML: New models for assessing carcinogenesis: An ongoing process. Toxicol Lett 120: 187-198, 2001.
25. Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, Shen MM, Cordon-Cardo C and Abate-Shen C: Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev 23(6): 675-80, 2009.
26. Hikosaka A, Ogawa K, Sugiura S, Asamoto M, Takeshita F, Sato S Y, Nakanishi M, Kohri K and Shirai T: Susceptibility of p27kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation. Int J Cancer 122: 1222-1228, 2008.
27. Ota T, Asamoto M, Toriyama-Baba H, Yamamoto F, Matsuoka Y, Ochiya T, Sekiya T, Terada M, Akaza H and Tsuda H: Transgenic rats carrying copies of the human c-Ha-ras proto-oncogene exhibit enhanced susceptibility to N-butyl-N-(4-hydroxybutyl)nitrosamine bladder carcinogenesis. Carcinogenesis 21(7): 1391-1396, 2000.
28. Tsuda H, Fukamachi K, Ohshima Y, Ueda S, Matsuoka Y, Hamaguchi T, Ohnishi T, Takasuka N and Naito A: High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model. Cancer Sci 96(6): 309-316, 2005.
29. Reis LO, Pereira TC, Favaro WJ, Cagnon VHA, Lopes-Cendes I and Ferreira U: Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 27(3): 353-361, 2009.
30. Wu XR: Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev 28: 281-290, 2009.
31. Gollapudi BB, Stott WT, Yano BL and Bus JS: Mode of action considerations in the use of transgenic animals for mutagenicity and carcinogenicity evaluations. Toxicol Lett 103: 479-484, 1998.
32. Garcia-Espana A, Salazar E, Sun TT, Wu XR and Pellicer A: Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior. Cancer Res 65(4): 1150-1157, 2005.
33. Hadaschik BA, Black PC, Sea JC, Metwalli AR, Fazli L, Dinney CP, Gleave ME and So AI: A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int 100: 1377-1348, 2007.
34. Chan E, Patel A, Heston W and Larchian W: Mouse orthotopic models for bladder cancer research. BJU Int 104(9): 1286-1291, 2009.
35. Jull W: The induction of tumours of the bladder epithelium in mice by the direct application of a carcinogen. Br J Cancer 5: 328-330, 1951.
36. Clayson DB and Cooper EH: Cancer of the urinary tract. Adv Cancer Res 13: 271-381, 1970.
37. Desesso JM: Confounding factors in direct bladder exposure studies. Comm Toxicol 3: 317-334, 1989.
38. Cohen SM and Lawson TA: Rodent bladder tumors do not always predict for humans. Cancer Lett 93(1): 9-16, 1995.
39. DeSesso JM: Proliferative lesions of the bladder: Their development and interrelationships. Comm Toxicol 3: 335-348, 1989.
40. Shirai T, Fukushima S, Tagawa Y, Okumura M and Ito N: Cell proliferation induced by uracil-calculi and subsequent development of reversible papillomatosis in the rat urinary bladder. Cancer Res 49: 378-383, 1989.
41. Fukushima S, Tanaka H, Asakawa E, Kagawa M, Yamamoto A and Shirai T: carcinogenicity of uracil, a nongenotoxic chemical, in rats and mice and its rationale. Cancer Res 52(7): 1675-1680, 1992.
42. Shirai T, Shibata M, Takahashi S, Tagawa Y, Imaida K and Hirose M: Differences in cell proliferation and apoptosis between reversible and irreversible mucosal lesions associated with uracil-induced urolithiasis in N-butyl-N-(4-hydroxybutyl)nitrosamine-pretreated. Carcinogenesis 16(3): 501-505, 1995.
43. Fukushima S and Murrai T: Calculi, precipitates and microcrystalluria associated with irritation and cell proliferation as a mechanism of urinary bladder carcinogenesis in rats and mice. IARC Sci Publ 147: 159-174, 1999.
44. Jones RF, Debiec-Rychter M and Wang CY: Chemical carcinogenesis of the urinary bladder - a status report. J Cancer Res Clin Oncol 118: 411-419, 1992.
45. Cohen SM: Role of cell proliferation in regenerative and neoplastic disease. Toxicol Lett 82-83: 15-21, 1995.
46. Fukushima S, Shibata MA, Shirai T, Tamano S and Ito N: Roles of urinary sodium ion concentration and pH in promotion by ascorbic acid of urinary bladder carcinogenesis in rats. Cancer Res 46(4.1): 1623-1626, 1986.
47. Lina BAR and van Garderen-Hoetmer A: effect of urinary pH on the progression of urinary bladder tumours. Food Chem Toxicol 37: 1159-1166, 1999.
48. González AB and Darby S: Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 363: 345-351, 2004.
49. Jung I, Messing E: molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control 7(4): 325-334, 2000.
50. Jaal J and Dörr W: Radiation-induced damage to mouse urothelial barrier. Radiother Oncol 80: 250-256, 2006.
51. Moon K, Stukenborg GJ, Keim J and Theodorescu D: Cancer incidence after localized therapy for prostate cancer. Cancer 107(5): 991-998, 2006.
52. Sountoulides P, Koletsas N, Kikidakis D, Paschalidis K and Sofikitis N: Secondary malignancies following radiotherapy for prostate cancer. Ther Adv Urol 2(3): 119-125, 2010.
53. Antonakopoulos GN, Hicks RM, Hamilton E and Berry RJ: Early and late morphological changes (including carcinoma of the urothelium) induced by irradiation of the rat urinary bladder. Br J Cancer 46: 403-416, 1982.
54. Stewart FA: Mechanism of bladder damage and repair after treatment with radiation and cytostatic drugs. Br J Cancer 53(Suppl. VII): 280-291, 1986.
55. Kunze E: Hyperplasia urinary bladder rat. In: Monographs on Pathology of Laboratory Animals. Urinary System. Second edition. Ed. Jones TC, Hard GC, Mohr U (eds.). Springer, New York, pp. 331-368, 1998.
56. Bulnes-Sesma S, Ullibarri-Ortiz de Zárate N and Lafuente-Sánchez JV: Tumour induction by ethylnitrosourea in the central nervous system. Rev Neurol 43(12): 733-738, 2006.
57. Pitot H and Dragan Y: Facts and theories concerning the mechanisms of carcinogenesis. FASEB J 5: 2280-2286, 1991.
58. Bryan GT: The pathogenesis of experimental bladder cancer. Cancer Res 37: 2813-2816, 1977.
59. Cohen SM: Promotion in urinary bladder carcinogenesis. Environ Health Perspect 50: 51-59, 1983.
60. Johansson SL and Cohen SM: Epidemiology and etiology of bladder cancer. Semin Surg Oncol 13: 291-298, 1997.
61. Cohen SM: Tresholds in genotoxicity and carcinogenicity: Urinary bladder carcinogenesis. Genes Envir 30(4): 132-138, 2008.
62. Burgués JP, Gómez L, Pontones JL, Vera CD, Jiménez-Cruz JF and Ozonas M: A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids. Eur Urol 51(4): 962-969, 2007.
63. Lin CW, Lin JC and Prout GR: Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 45: 5070-5079, 1985.
64. Hatina J, Huckenbeck W, Rieder H, Seifert HH and Schulz WA: Harnblasenkarzinomzelllinien Als modellsysteme zur pathobiologie des harnblasenkarzinoms. Der Urologe 6: 724-734, 2008.
65. Wang F, Wu J, Tian Y, Chen X, Hu H, Wu W, Li C and Huang Q: Role of VEGF in the growth and metastasis of a murine bladder carcinoma. Chin Sci Bull 48(22): 2404-2410, 2003.
66. Yang N, Li SH, Lü YZ, Chen LS and Ren DM: Attenuated Salmonella typhimurium carrying shRNA-expressing vectors elicit RNA interference in murine bladder tumors. Acta Pharmacol Sin 32(3): 368-374, 2011.
67. Crallan RA, Georgopoulos NT and Southgate J: Experimental models of human bladder carcinogenesis. Carcinogenesis 27(3): 374-381, 2006.
68. Lijinsky W: Chemistry and biology of N-nitroso compounds. In: Cambridge Monographs on Cancer Research. Cambridge University Press, Cambridge UK, 1992.
69. Druckrey H, Preussmann R, Ivankovic S, Schmidt CH, Mennel HD and Stahl KW: Selective induction of bladder cancer in rats by dibutyl- and N-butyl-N-butanol(4)-nitrosamine. Z Krebsforsch 2(66): 280-90, 1964.
70. Okada M and Ishidate M: Metabolic fate of N-butyl-N-(4-hydroxybutyl)- nitrosamine and its analogues: Selective induction of urinary bladder tumours in the rat. Xenobiotica 7(1): 11-24, 1977.
71. Suzuki E, Anjo T, Aoki J and Okada M: Species variations in the metabolism of N-butyl-N-(4-hydroxybutyl)nitrosamine and related compounds in relation to urinary bladder carcinogenesis. Gann 74: 60-68, 1983.
72. Ito N, Shirai T, Fukushima S and Hirose M: Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. J Cancer Res Clin Oncol 108: 169-173, 1984.
73. Ohtani M, Kakizoe T, Nishio Y, Sato S, Sugimura T, Fukushima S and Niijima T: Sequential changes of mouse bladder epithelium during induction of invasive carcinomas by N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Res 46: 2011-2004, 1986.
74. Wanibuchi H, Wei M, Salim EI, Kinoshita A, Morimura K, Sudo K and Fukushima S: Inhibition of rat urinary bladder carcinogenesis by the antiangiogenic drug TNP-470. Asian Pac J Cancer Prev 7: 101-107, 2006.
75. Hashimoto Y, Suzuki K and Okada M: Induction of urinary bladder tumors by intravesicular instillation of butyl(4-hydroxybutyl)nitrosoamine and its principal urinary metabolite, butyl(3-carboxypropyl)nitrosoamine in rats. Gann 65: 69-73, 1974.
76. Fuji K, Odashima S and Okada M: Induction of tumours by administration of N-dibutylnitrosamine and derivatives to infant mice. Br J Cancer 35: 610-614, 1977.
77. Tsuda H, Miyata Y, Hagiwara A, Hasegawa R, Shirai T and Ito N: Damage and repair of DNA in urinary bladder epithelium of rats treated with N-butyl-N-(4-hydroxybutyl) nitrosamine. Gann 68: 781-783, 1977.
78. Cohen SM: Urinary bladder carcinogenesis. Toxicol Pathol 26: 121-127, 1998.
79. Kunze E, Schauer A and Schatt S: Stages of transformation in the development of N-butyl-N-(4-hydroxybutyl) nitrosamine-induced transitional cell carcinomas in the urinary bladder of rats. Z Krebsforsch Klin Onkol 87(2): 139-160, 1976.
80. Atcha Z, Rourke C, Neo AHP, Goh CWH, Lim JSK, Aw CC, Browne ER and Pemberton DJ: Alternative method of oral dosing for rats. J Am Assoc Lab Anim Sci 49(3): 335-343, 2010.
81. Hoggatt A, Hoggatt J, Honerlaw M and Pelus LM: A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice. J Am Assoc Lab Anim Sci 4(3): 329-334, 2010.
82. Oliveira PA, Pires MJ, Nóbrega C, Arantes-Rodrigues R, Calado AM, Carrola J, Ginja M and Colaço A: Technical report: Technique of bladder catheterization in female mice and rats for intravesical instillation in models of bladder cancer. Scand J Lab Anim Sci 36(1): 5-9, 2009.
83. Bonfanti M, Magagnotti C, Bonati M, Fanelli R and Airoldi L: Pharmacokinetic profile and metabolism of N-nitrosobutyl-(4-hydroxybutyl)amine in rats. Cancer Res 48: 3666-3669, 1988.
84. Mirvish SS: Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric, esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 93: 17-48, 1995.
85. Iida K, Itoh K, Maher JM, Kumagai Y, Oyasu R, Mori Y, Shimazui T, Akaza H and Yamamoto M: Nrf2 and p53 cooperatively protect against BBN-induced urinary bladder carcinogenesis. Carcinogenesis 28(11): 2398-2403, 2007.
86. Suzuki E and Okada M: Metabolic fate of N-butyl-N-(4-hydroxybutyl) nitrosamine in the rat. Gann 71(6): 856-862, 1980.
87. Mochizuki M, Suzuki E and Okada M: Structure and metabolic fate of N-nitrosodialkylamines in relation to their organotropic carcinogenicity with special reference to induction of urinary bladder tumors. Yakugaku Zasshi 117(10-11): 884-894, 1997.
88. Cohen SM, Ohnishi T, Clark NM, He J and Arnold LL: Investigations of rodent urinary bladder carcinogens: collection, processing, and evaluation of urine and bladders. Toxicol Pathol 35(3): 337-347, 2007.
89. Airoldi L, Magagnotti C, Bonfanti M and Fanelli R. Development of an experimental model for studying bladder carcinogen metabolism using the isolated rat urinary bladder. Cancer Res 47: 3697-3700, 1987.
90. Yamamoto K, Nakata D, Tada M, Tonoki H, Nishida T, Hirai A, Ba Y, Aoyama T, Hamada J, Furuuchi K, Harada H, Hirai K, Shibahara N, Katsuoka Y and Moriuchi T: A functional and quantitative mutational analysis of p53 mutations in yeast indicates strand biases and different roles of mutations in DMBA- and BBN-induced tumors in rats. Int J Cancer 83: 700-705, 1999.
91. Oliveira PA, Palmeira C, Colaço A, de la Cruz LF and Lopes C: DNA content analysis, expression of Ki-67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl)nitrosamine and treated with mitomycin C and bacillus Calmette-Guérin. Anticancer Res 26(4B): 2995-3004, 2006.
92. Vasconcelos-Nóbrega C, Colaço A, Santos L, Vala H, Palomino LF, Lopes C and Oliveira PA: Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions. Anticancer Res 31(5): 1637-1642, 2011.
93. Oliveira PA, Arantes-Rodrigues R, Sousa-Diniz C, Colaço A, Lourenço L, De La Cruz LF, Da Silva VM, Afonso J, Lopes C and Santos L: The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res 29(8): 3221-6, 2009.
94. Ito N, Fukushima S, Shirai T and Nakanishi K: Effects of promoters on N-butyl-N-(4-hydroxybutyl)nitrosamine induced urinary bladder carcinogenesis in the rat. Environ Health Perspect 50: 61-69, 1983.
95. Ohtani M, Kakizoe T, Sato S, Sugimura T and Fukushima S: Strain differences in mice with invasive bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. J Cancer Res Clin Oncol 112(2): 107-10, 1986.
96. Oyasu R: Epithelial tumours of the lower urinary tract in humans and rodents. Food Chem Toxicol 33(9): 747-755, 1995.
97. Oliveira PA, Colaço A, De La Cruz Palomino LF and Lopes C: Rat and mouse urothelial carcinogenesis. Exp Pathol Health Sci 2(1): 23-28, 2008.
98. Okajima E, Hiramatsu T, Hirao K, ljuin M, Hirao Y, Babaya K, Ikuma S, Ohara S, Shiomi T, Hijioka T and Ohishi H: Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in dogs. Cancer Res 41: 1958-1966, 1981.
99. Hirao Y, Sasaki K, Sanma S, Ozono S, Babaya K and Okajima E: Scanning electron microscopy of changes in the urinary bladder in dogs treated with N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). Urol Res 15(1): 25-9, 1987.
100. Higashi S, Murai T, Mori S, Kamoto T, Yoshitomi M, Arakawa Y, Makino S, Fukushima S, Yoshida O and Hiai H: Host genes affecting survival period of chemically induced bladder cancer in mice. J Cancer Res Clin Oncol 124(12): 670-676, 1998.
101. Boorman GA, Wood M and Fukushima S: Tumours of the urinary bladder. IARC Sci Publ 111: 383-406, 1994.
102. Murai T, Mori S, Hosono M, Takeuchi Y, Ohara T, Makino S, Takeda R, Hayashi Y and Fukushima S: Renal pelvic carcinoma which shows metastatic potential to distant organs, induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in NON/Shi mice. Jpn J Cancer Res 82(12): 1371-1377, 1991.
103. Vasconcelos-Nóbrega C, Pinto-Leite R, Arantes-Rodrigues R, Ferreira R, Brochado P, Cardoso ML, Palmeira C, Salvador A, Guedes-Teixeira CI, Colaço A, Palomino LF, Lopes C, Santos L and Oliveira PA: In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol, 2011 Dec 9. [Epub ahead of print].
104. Gofrit ON, Birman T, Dinaburg A, Ayesh S, Ohana P and Hochberg A: Chemically induced bladder cancer-a sonographic and morphologic description. Urology 68(1): 231-235, 2006.
105. Ohyama C, Kawamura S, Satoh M, Saito S, Yoshikawa K, Hoshi S and Orikasa S: Endoscopic observation for detection and monitoring of N-butyl-N-(4- hydroxybutyl)nitrosamine induced bladder tumor in rats. Urol Res 25(3): 183-186, 1997.
106. Asanuma H, Arai T, Seguchi K, Kawauchi S, Satoh H, Kikuchi M and Murai M: Successful diagnosis of orthotopic rat superficial bladder tumor model by ultrathin cystoscopy. J Urol 169(2): 718-720, 2003.
107. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I and Moore RB: Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81(4): 638-646, 1999.
108. Kikuchi E, Xu S, Ohori M, Matei C, Lupu M, Menendez S, Koutcher JA and Bochner BH: Detection and quantitative analysis of early stage orthotopic murine bladder tumor using in vivo magnetic resonance imaging. J Urol 170(4 Pt 1): 1375-1378, 2003.
109. Johnson AM, Conover DL, Huang J, Messing EM, Ning R, O'connell MJ, Rossi MA, Sun TT, Wood RW, Wu XR and Reeder JE: Early detection and measurement of urothelial tumors in mice. Urology 67(6): 1309-1314, 2006.
110. Chan E, Patel A, Heston W and Larchian W: Mouse orthotopic models for bladder cancer research. BJU Int 104: 1286-1291, 2009.
111. van der Horst G, van Asten JJ, Figdor A, van den Hoogen C, Cheung H, Bevers RF, Pelger RC and van der Pluijm G: Real-time cancer cell tracking by bioluminescence in a preclinical model of human bladder cancer growth and metastasis. Eur Urol 60(2): 337-343, 2011.
112. Fadl-Elmula I: Chromosomal changes in uroepithelial carcinomas. Cell Chromosom 4(1): 2005.
113. Oliveira PA, Adega F, Palmeira CA, Chaves RM, Colaço AA, Guedes-Pinto H, De la Cruz P LF and Lopes CA: DNA study of bladder papillary tumours chemically induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in Fisher rats. Int J Exp Pathol 88(1): 39-46, 2007.
114. Masui T, Mann AM, Macatee TL, Okamura T, Garland EM, Smith RA and Cohen SM. Absence of Ras oncogene activation in rat urinary bladder carcinomas induced by N-methyl-N-nitrosourea or N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 13(12): 2281-2285, 1992.
115. Masui T, Dong Y, Yamamoto S, Takada N, Nakanishi H, Inada KI, Fukushima S and Tatematsu M: p53 mutations in transitional cell carcinomas of the urinary bladder in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Cancer Lett 105: 105-112, 1996.
116. Ariel I, Ayesh S, Gofrit O, Ayesh B, Abdul-Ghani R, Pizov G, Smith Y, Sidi AA, Birman T, Schneider T, Groot N and Hochberg A: Gene expression in the bladder carcinoma rat model. Mol Carcinog 41: 69-76, 2004.
117. Yao R, Yi Y, Grubbsy CJ, Lubetz RA and You M: Gene expression profiling of chemically induced rat bladder tumors. Neoplasia 9(3): 207-221, 2007.
118. Yamamoto S, Chen T, Murai T, Mori S, Morimura K, Oohara T, Makino S, Tatematsu M, Wanibuchi H and Fukushima S: Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis 18(10): 1877-1882, 1997.
119. Ogawa K, Uzvolgyi E, St. John MK, Oliveira ML, Arnold L and Cohen SM: Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in B6D2F1 mice. Mol Carcinog 21: 70-79, 1998.
120. Yao R, Lemon WJ, Wang Y, Grubbsy CJ, Lubetz RA and You M: Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl) nitrosamine. Neoplasia 6(5): 569-577, 2004.
121. Wu XR, Sun TT, McConkey DJ, Shrader M and Papageorgiou A: Animal models of bladder cancer. In: Textbook of Bladder Cancer. Lerner SP and Schoenberg MP (eds.). Taylor & Francis, United Kingdom, pp. 157-169, 2006.
122. Niell HB, Mickey DD, Soloway LS and Wood CA: Growth characteristics of N- [4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT)-induced mouse bladder tumor lines in a human tumor cell stem assay. Cancer 49: 323-330, 1982.
123. Drago JR: The Noble rat bladder cancer model - FANFT-induced tumours. Cancer 53: 1093-1099, 1984.
124. Swaminathan S and Bryan GT: Biotransformation of the bladder carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide in mice. Cancer Res 44: 2331-2338, 1984.
125. Spry LA, Zenser TV, Cohen SM and Davis BB: Role of renal metabolism and excretion in 5-nitrofuran-induced uroepithelial cancer in the rat. J Clin Invest 76: 1025-1031, 1985.
126. Lijinsky W: Species differences in nitrosamine carcinogenesis. J Cancer Res Clin Oncol 108: 46-55, 1984.
127. Cui L, Shi Y, Daib G, Panb H, Chen J, Song L, Wang S, Chang HC, Sheng H and Wang X: Modification of N-methyl-N-nitrosourea initiated bladder carcinogenesis in Wistar rats by terephthalic acid. Toxicol Appl Pharmacol 210: 24-31, 2006.
128. Reis LO, Faváro WJ, Ferreira U, Billis A, Fazuoli MG and Cagnon VHA: Evolution on experimental animal model for upper urothelium carcinogenesis. World J Urol 28: 499-505, 2010.
129. Swan PF: The rate of breakdown of methyl methanesulphonate, dimethyl sulphate and N-methyl-N-nitrosourea in the rat. Biochem J 110: 49-52, 1968.
130. Steinberg GD, Brendler CB, Ichikawa T, Squire RA and Isaacs JT: Characterization of an N-methyl-N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res 50: 6668-6674, 1990.